SLC2A1 and Alzheimer disease: Clinical and basic research evidence suggests that astrocytes are deeply involved in the pathological process of AD through dysregulation of the metabolic regulatory network: impaired glucose metabolism triggered by downregulation of the expression of the glucose transporter GLUT1 occurs in the early stages of the disease, leading to inadequate neuronal energy supply [90].